Brought to you by 
Newly formed Coronado division DiaVax gets CMV vaccines from City of Hope
16 Nov 2021
Executive Summary
Coronado Biosciences Inc. created DiaVax Biosciences to develop cytomegalovirus (CMV) immunotherapies concurrently in-licensed from City of Hope.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Newly formed Coronado division DiaVax gets CMV vaccines from City of Hope
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice